Soligenix, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher J. Schaber
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 29 Emmons Drive Princeton NJ United States of America 08540
- IPO Date
- Apr 4, 1994
- CIK
- 0000812796
- Website
- soligenix.com
- Similar Companies
- Business
- Soligenix, Inc. is a biopharmaceutical firm in its advanced development stages, dedicated to the discovery and commercialization of therapeutic agents addressing rare medical conditions within the United States. The company’s operations are divided into two distinct divisions: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment advances SGX301 (HyBryte), a distinctive photodynamic treatment, which successfully concluded an initial Phase 3 clinical investigation for addressing cutaneous T-cell lymphoma. Following regulatory feedback, a confirmatory Phase 3 study (FLASH2) is actively enrolling patients, with an interim analysis slated for the second quarter of 2026 and principal data expected in the latter half of 2026. This division also progresses SGX942 (dusquetide), an innate defense regulator platform, currently in Phase 3 trials for managing inflammatory conditions like oral mucositis in patients undergoing head and neck cancer treatment. Further pipeline assets include proprietary oral formulations of beclomethasone 17,21-dipropionate, such as SGX203 for pediatric Crohn's disease, and SGX302 (synthetic hypericin) which is undergoing a Phase 2a clinical trial for mild-to-moderate psoriasis, with top-line results anticipated in the fourth quarter of 2025. Additionally, SGX945, another innate defense regulator, is in a Phase 2a study for Behçet's disease, with top-line data expected in the third quarter of 2025. The Public Health Solutions segment is committed to developing RiVax, a vaccine candidate targeting ricin toxin, which has completed Phase 1a, 1b, and 1c clinical evaluations. This program is pursuing regulatory approval under the FDA’s Animal Rule and holds Fast Track and Orphan Drug designations. The segment also includes SGX943, a preclinical therapeutic designed for antibiotic-resistant and emergent infectious diseases, along with ThermoVax, a technology in early development aimed at enhancing vaccine thermostability. Furthermore, efforts are underway for vaccine candidates against filoviruses such as Marburg (MarVax) and Ebola (SuVax), which have received Orphan Drug designations, and CiVax for COVID-19 prevention, emphasizing the heat-stabilization technology. These public health initiatives are significantly bolstered by non-dilutive government grants and contracts. Initially established as DOR BioPharma, Inc., the company adopted the name Soligenix, Inc. in 2009. Soligenix was formed in 1987 and maintains its corporate headquarters in Princeton, New Jersey.
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
Soligenix to Present at BIO Investment & Growth Summit
Soligenix Details Recent Progress and Upcoming Milestones
Short Interest in Soligenix Inc. (NASDAQ:SNGX) Decreases By 12.5%
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space